Panel 1: The Future of Pricing and Reimbursement
Heather Steinfield, Moderator
Heather focuses on activities such as development of global payer value stories and tools for their implementation, moderation of payer/market access advisory boards and internal client workshops, assessment of US public and private payer policy, development of pricing and market access strategies, development of reimbursement strategic plans and specialty distribution programs, HCPCS and CPT coding assessments, and coding applications.
Prior to joining SKP, Heather served as a senior strategist for Quintiles Strategic Research Services, combining brand strategy with Phase IIIb and IV clinical research. At The Lewin Group, she was also a senior manager in the reimbursement strategy group.
Prior to joining Quintiles Strategic Research Services, Heather served as Manager of Reimbursement Programs for PAREXEL's Medical Marketing Services Division. Also with PAREXEL, she served as Market Analyst conducting strategic market assessments and other pre-launch activities.
Heather earned a B.A. in Health and Society from the University of Rochester.
Ira Klein, M.D., Panelist
Ted Haack, Panelist
He started at Pfizer in 2004 in Global Pricing & Reimbursement, responsible for endocrinology, smoking cessation, and thrombosis products, and P&R issues in Europe, Canada, Africa/Middle East and the United States. In 2009, he spent 6 months working in Rwanda as a Pfizer Global Health Fellow and was subsequently appointed Head of Pricing & Reimbursement, Primary Care BU, and was Interim Head of Market Access for PCBU from November 2011 through July 2012. Prior to Pfizer, he spent 7 years at Schering-Plough working with Latin America/Far East finance, Europe/Canada finance, and spent 6 months working in controlling at Essex Pharma, Schering-Plough's German subsidiary.
Ted began his career at Deloitte & Touche in Audit and Advisory Services, including two years in Frankfurt, Germany in the manufacturing practice. He has a BS degree in accounting from Villanova University, a Master of Arts in International Affairs from The Fletcher School of Law & Diplomacy at Tufts University, and an MBA from the Leonard N. Stern School of Business at New York University. He speaks fluent German in addition to his native English.
Panel 2: Building Successful Healthcare Start-ups in Today's Challenging Environment
Jonathan Fleming, Moderator
Mr. Fleming is also the director of several companies including Dicerna Pharmaceuticals, Lab Partners, Radius Pharmaceuticals, Greenlight and Railrunner. In addition, Mr. Fleming is also a director of Leerink Swann, a member of the board of the New England Health Initiative, a member of the Scientific Advisory Board at the Massachusetts Life Science Center, and a trustee of the Museum of Science in Boston. Mr. Fleming is also a lecturer at the MIT Sloan School of Business and at Harvard Medical School.
Jose-Carlos Gutierrez-Ramos, Ph.D., Panelist
Prior to joining Pfizer, JC was Senior Vice President and Head of the Immunoinflammation Center for Drug Discovery (iiCEDD) at Glaxo Smith Kline. JC built the iiCEDD as a global group of "drug hunters" that included biologists, chemists, pharmacologists, protein scientists, clinicians and business developers who were responsible for drug discovery and development through Phase IIa (Proof of Concept).
Prior to GSK, JC held positions including the Site Head and Chief Scientific Officer (CSO) at AMGEN Mountain View, the Senior Vice President of R&D at Avidia, where he led a significant effort of novel protein therapeutics for autoimmune disease, CSO of Peptimmune Inc. in Cambridge, MA, where he was responsible for the development of peptide based therapeutics for autoimmune disease, including multiple sclerosis and diabetes, and Vice President, Inflammation at Millennium Pharmaceuticals, where he was responsible for advancing preclinical candidates in Inflammation & Immunology to human trials and advancing compounds (small molecules and antibodies) from discovery through clinical development.
JC was also part of the Faculty at the Genetics department of Harvard Medical School, where he led a major research team at the Center for Blood Research that generated more than 150 peer-reviewed publications. Before coming to the US, he was member of the Basel Institute for Immunology in Basel, Switzerland, and a fellow at the Max-Plank for Immunbiologie in Freiburg, Germany. JC received his master's degree in Chemistry and his Ph.D. in Immunochemistry at the Autónoma University of Madrid, Spain.
Glenn Batchelder, Panelist
Jenna Rose, Panelist
Robert Tepper, M.D., Panelist
Outside of Third Rock, Dr. Tepper is an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital. He is also an advisory board member of several health care institutions including Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Tufts Medical School. He also serves on the Council of the National Center for the Advancement of Translational Sciences (NCATS) at the National Institutes of Health (NIH).
Panel 3: Healthcare IT: Beyond the Desktop
C. William Hanson III, M.D., Moderator
His research using "electronic nose" technology to detect diseases such as pneumonia and sinusitis by breath analysis has been featured in Scientific American. He recently published The Edge of Medicine: The Technology That Will Change Our Lives, a non-fiction book profiling innovations in biotechnology that are changing the delivery of medical care and the ways in which they're altering the human experience.
Also in a recently published, Smart Medicine: How the Changing Role of Doctors Will Revolutionize Health Care, Dr. Hanson reveals the revolutionary changes that will soon be sweeping through the medical community. Dr. Hanson's research has been featured in national and international publications, including Popular Science, U.S. News and World Report, and has been a guest on NPR's Fresh Air as well as television documentaries on the Discovery Channel.
John D. Halamka, M.D., M.S., Panelist
As Chief Information Officer of Beth Israel Deaconess Medical Center, he is responsible for all clinical, financial, administrative and academic information technology serving 3000 doctors, 14000 employees and two million patients. As Chairman of NEHEN he oversees clinical and administrative data exchange in Eastern Massachusetts. As co-Chair of the HIT Standards Committee he facilitates the process of electronic standards harmonization among stakeholders nationwide. As co-Chair of the Massachusetts HIT Advisory Committee, he engages the stakeholders of the Commonwealth to guide the development of a statewide health information exchange.
Scott Andrews, Panelist
Anmol Madan, Ph.D., Panelist
Lauren Fifield, Panelist
Panel 4: Innovation in Therapeutics: Drugs of the Future
Navjot Singh, Ph.D., Moderator
Tim Harris, Ph.D., Panelist
Anne De Groot, M.D., Panelist
De Groot has received uninterrupted federal funding for her research activities through multiple NIH and foundation grants since 1989. She was the recipient of a National Foundation for Infectious Diseases-Eli Lilly Award, two Rhode Island Foundation awards and a Commercial Innovation Award (RI Center for Cellular Medicine). In addition, she was recognized as one of the "Best and the Brightest" in Science and Technology by Esquire Magazine (2003). She has published more than 150 articles and chapters describing the development of epitope-driven vaccines and the application of immunoinformatics tools. In addition to her active research on vaccines for HIV, TB, Tularemia, Smallpox and EBV, she is a pioneer in the field of deimmunizing protein therapeutics.
Prof. Ehud Gazit, Ph.D., Panelist
From 2008-2012 Gazit served as Tel Aviv University Vice President for Research and Development and the Chairman of the board of directors of Ramot Ltd., the technology transfer company of Tel Aviv University. Gazit's technology transfer achievements was acknowledged by inclusion in the 2008 list of 100 Innovations from academic Research to Real-World Application by the Association of University Technology Managers (AUTM) and in a list of 100 Technology Offers stemming from EU Biotechnology RTD results of three Research Framework Programmes (FP5, FP4, and FP3).
Gazit's research focused on the study of biomolecular self-assembly. His work was published in some of the most prestigious academic journals including Science, Nature Nanotechnology, Nature Chemical Biology, and Cell. He is also the inventor of few tens of patent applications. In 2009 he received the Herstin Award for a leading scientist under the age of 44, and elected in 2012 as a fellow of the Royal Society of Chemistry (FRSC). Gazit is or was on the editorial board of several journals including Nanomedicine, PLoS ONE, Amyloid, and Current Chemical Biology.
Gazit holds a B.Sc. from Tel Aviv University and a Ph.D. from Weizmann Institute of Science, for which he received the John F. Kennedy Award in 1996. He has been a faculty member at Tel Aviv University since 2000, after completing his postdoctoral studies at Massachusetts Institute of Technology (MIT) where he also had held a visiting appointment (2002-2011).
Eric Perakslis, Ph.D., Panelist
Prior to FDA, Eric was Senior Vice President of R&D Information Technology at Johnson & Johnson Pharmaceuticals R&D and was a member of the Corporate Office of Science and Technology. During his thirteen years at J&J, Eric also held the posts of Vice President R&D Informatics, Vice President and Chief Information Officer, Director of Research Information Technology as well as assistant Director and Director of Drug Discovery Research prior to his current role. Before joining J&J, Eric was the Group leader of Scientific Computing at ArQule Inc. and he began his professional career with the Army Corps of Engineers.
Eric has a PhD in chemical and biochemical engineering from Drexel University and also holds B.S.Che and M.S. degrees in chemical engineering. Eric's current research interests are enterprise knowledge management, patient stratification, healthcare IT and translational informatics with the specific focus precompetitive data sharing, and open source systems globalization.
Eric is a late-stage kidney cancer survivor and an avid patient advocate. He has served as the Chairman of the Survivor Advisory Board at the Cancer Institute of New Jersey and as the Chief Information Officer of the King Hussein Institute for Biotechnology and Cancer in Amman, Jordan. Eric has also worked extensively with the Lance Armstrong Foundation, the Kidney Cancer Association, the Scientist Survivor program of the American Association for Cancer Research, OneMind4Research and several other top non-profit disease-based organizations to further their domestic and international agendas.
Eric's personal interests include sailboat racing, back-country snowboarding, rock climbing, cycling, running marathons and operating his family vineyard and winery. Eric lives in Doylestown, Bucks County Pennsylvania with his wife Lisa Gail and 11-year old daughter Sammy.